Daniel De Magalhaes Filho is the founder of CDMF Bioconsulting and co-founder of Valora Therapeutics. Daniel is a PhD immuno-oncologist researcher with 20 years of research experience.

As a consultant Daniel is helping pharmaceutical companies and CROs mainly with precision medicine and biomarker strategy but also with clinical and preclinical development.

Previously as a Principal Scientist at Rakuten Medical, his research focused on two areas. The first one related to biomarkers and understanding the mechanism of action of the drug in patients, including the discovery of predictive biomarkers. Working with several other members of the team as well as with external collaborators and CROs, Daniel uncovered two sets of biomarkers that might predict which patients would benefit from the drug. He also led the overall biomarker strategy, from clinical protocol implementation to analysis, in four additional clinical trials.

The second aspect of his research at Rakuten Medical involved preclinical models, where he characterized the immunological cell death induced by photoimmunotherapy, led the preclinical development of a new drug, and collaborated on various projects driven by other members of the translational sciences team.

Prior to his tenure at Rakuten Medical, Daniel worked in the JLABS San Diego incubator for Epicentrx, a startup company developing oncolytic virus. There he was also involved heavily with biomarkers and preclinical research, characterizing immunological response of patients treated with Epicentrx oncolytic virus, and engineering in vitro and in vivo oncolytic virus strains armed with immunomodulators.

Daniel obtained his PhD in physiology and physiopathology from Paris VI University (Paris, France) and completed his postdoctoral studies at the Salk Institute in San Diego, first in Andy Dillin lab, and then in Ron Evans lab. At the Salk Institute, he worked on several projects related to aging, cancer, immunology, metabolism and neurodegenerative diseases. His academic and industry work resulted in 15 peer reviewed publications including in Cell, Cell Reports, and Nature Communications. As he transitioned to the pharmaceutical industry, Daniel also obtained an MBA focused on how to start a scientific company.